ReviewJournal of cardiovascular translational research2017
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
Review in Journal of cardiovascular translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials.BMC medical research methodology · 2023Pooled it
- Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.Nature medicine · 2021Trial
- Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.Circulation. Cardiovascular quality and outcomes · 2025Article
- Review
- Evolution of Research on Artificial Intelligence for Heart Failure: A Bibliometric and Visual Analysis.Journal of multidisciplinary healthcare · 2025Review
- The Introduction of AI Into Decentralized Clinical Trials: Preparing for a Paradigm Shift.JACC. Advances · 2024Article
- An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials.NPJ digital medicine · 2023Article
- Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature.Biomolecules · 2023Review
- Update on Atrial Shunt Therapy for Treatment of Heart Failure.Structural heart : the journal of the Heart Team · 2022Review
- Review
- Review
- Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths.Current cardiology reports · 2022Review
- The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- Innovative highlights of clinical drug trial design.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.Circulation · 2020Review
- Different Pathophysiology and Outcomes of Heart Failure With Preserved Ejection Fraction Stratified by K-Means Clustering.Frontiers in cardiovascular medicine · 2020Article
- 20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2019Article
- Prominent 'Y' descent is an ominous sign of a poorer prognosis in heart failure with preserved ejection fraction.ESC heart failure · 2019Article
- Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.Annual review of pharmacology and toxicology · 2019Review
- Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale.Therapeutic advances in chronic disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
A major challenge in the care of patients with heart failure and preserved ejection fraction (HFpEF) is the lack of proven therapies due to disappointing results from randomized controlled trials (RCTs). The heterogeneity of the HFpEF syndrome and the use of conventional RCT designs are possible reasons underlying the failure of these trials. There are several factors-including the widespread adoption of electronic health records, decreasing costs of obtaining high-dimensional data, and the availability of a wide variety of potential therapeutics-that have evolved to enable more innovative clinical trial designs in HFpEF. Here, we review the current landscape of HFpEF RCTs and present several innovative RCT designs that could be implemented in HFpEF, including enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning-based trials (including examples for each). Our hope is that the description of the aforementioned innovative trial designs will stimulate new approaches to clinical trials in HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.